Jingjing Jiang

8PUBLICATIONS
160CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 11, 2026
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

|Jun 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers.

|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.

|Feb 11, 2026
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.

Xing Wei, Cristina Blaj, M Ali Al-Radhawi

|Jul 24, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.

Caroline Weller, G Leslie Burnett, Lingyan Jiang

|Apr 29, 2025
A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma.

Caroline Broderick, Riccardo Mezzadra, Exequiel M Sisso

Pageof 2

Frequent Collaborators

8 joint publications

Mallika Singh

6 joint publications

Jacqueline A M Smith

5 joint publications

Matthew Holderfield

4 joint publications

Lingyan Jiang